PCH
SYRE icon

Polar Capital Holdings’s Spyre Therapeutics SYRE Stock Holding History

Polar Capital Holdings’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.7M Buy
988,009
+195,162
+25% +$14.2M 0.21% 92
2026
Q1 		$40M Buy
792,847
+52,521
+7% +$1.98M 0.14% 117
2025
Q4 		$24.3M Sell
740,326
-48,462
-6% -$1.27M 0.09% 145
2025
Q3 		$13.2M Buy
788,788
+43,788
+6% +$714K 0.06% 182
2025
Q2 		$11.2M Sell
745,000
-80,000
-10% -$1.18M 0.06% 181
2025
Q1 		$13.3M Buy
825,000
+75,000
+10% +$1.56M 0.08% 175
2024
Q4 		$17.5M Buy
750,000
+250,000
+50% +$7.33M 0.1% 154
2024
Q3 		$14.7M Hold
500,000
– – 0.07% 169
2024
Q2 		$11.8M Hold
500,000
– – 0.07% 170
2024
Q1 		$19M Hold
500,000
– – 0.1% 150
2023
Q4 		$10.8M Buy
500,000
+200,000
+67% +$2.76M 0.07% 191
2023
Q3 		$3.67M Buy
+300,000
New +$3.97M 0.03% 239

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Polar Capital Holdings's SYRE Position: Q2 2026 in Review

Polar Capital Holdings increased its Spyre Therapeutics (SYRE) stake by 25% in Q2 2026, buying an estimated $14.2M and bringing the position to 988,009 shares worth $87.7M. The position accounts for 0.21% of the portfolio, ranked #92.

Polar Capital Holdings first reported a position in SYRE in Q3 2023 and has held it in 12 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Polar Capital Holdings held 988,009 shares of Spyre Therapeutics worth $87.7M as of Q2 2026.
  • Polar Capital Holdings bought 195,162 Spyre Therapeutics shares in Q2 2026, an estimated $14.2M.
  • Spyre Therapeutics made up 0.21% of Polar Capital Holdings's portfolio in Q2 2026, its #92 holding.
  • Polar Capital Holdings first reported a position in Spyre Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.